Page 120 - 《中国药房》2023年22期

综上所述，在耐药革兰氏阴性菌感染的治疗中，多 Ceftolozane-tazobactam vs. colistin for the treatment of
黏菌素的肾毒性发生率较高，且多黏菌素E高于多黏菌 infections due to multidrug-resistant Pseudomonas aerugi‐
素B。本研究的局限性为：（1）纳入的研究数量有限；（2） nosa：a multicentre cohort study[J]. J Glob Antimicrob Re‐
给药剂量不一致，且缺乏用药剂量的具体数据，无法针 sist，2022，28：288-294.
对剂量进行亚组分析；（3）有部分研究将肾毒性发生率 [11] ALMANGOUR T A，GHONEM L，ALJABRI A，et al.
Ceftazidime-avibactam versus colistin for the treatment of
作为次要结局，因此关于肾毒性发生率的数据有限。可
infections due to carbapenem-resistant enterobacterales：a
见，本研究所得结论尚需更多高质量研究进一步证实。
参考文献 multicenter cohort study[J]. Infect Drug Resist，2022，15：
211-221.
[ 1 ] NORDMANN P，POIREL L. Epidemiology and diag- [12] HEYBELI C，CANASLAN K，OKTAN M A，et al. Acute
nostics of carbapenem resistance in Gram-negative bacteria kidney injury following colistin treatment in critically-ill
[J]. Clin Infect Dis，2019，69（Suppl 7）：S521-S528.
patients：may glucocorticoids protect? [J]. J Chemother，
[ 2 ] SANGTHAWAN P，GEATER A F，NAORUNGROJ S，et 2021，33（2）：85-94.
al. Characteristics，influencing factors，predictive scoring [13] BABAR Z U，DODANI S K，NASIM A. Treatment out‐
system，and outcomes of the patients with nephrotoxicity come and adverse effects of colistin in adult patients with
associated with administration of intravenous colistin[J].
Antibiotics，2021，11（1）：2. carbapenem-resistant Gram-negative bacteremia from
[ 3 ] ALOTAIBI F M，ALSHEHAIL B M，AL JAMEA Z A H， Pakistan[J]. Int J Infect Dis，2021，106：171-175.
[14] BROWN M L，MOTSCH J，KAYE K S，et al. Evaluation
et al. Incidence and risk factors of colistin-induced nephro‐
toxicity associated with the international consensus guide‐ of renal safety between imipenem/relebactam and colistin
lines for the optimal use of the polymyxins：a retrospec‐ plus imipenem in patients with imipenem-nonsusceptible
tive study in a tertiary care hospital，Saudi Arabia[J]. Anti‐ bacterial infections in the randomized，phase 3 RESTORE-
biotics，2022，11（11）：1569. IMI 1 study[J]. Open Forum Infect Dis，2020，7（3）：ofaa054.
[ 4 ] 刘昌伟，胡立芬，汪燕燕，等 . 多黏菌素 B 治疗耐碳青霉 [15] POURHEIDAR E，HAGHIGHI M，KOUCHEK M，et al.
Comparison of intravenous ampicillin-sulbactam plus
烯革兰阴性菌脓毒症的疗效和肾毒性[J]. 上海医药，
2022，43（13）：26-28，50. nebulized colistin with intravenous colistin plus nebulized
LIU C W，HU L F，WANG Y Y，et al. Effectiveness and colistin in treatment of ventilator associated pneumonia
nephrotoxicity of polymyxin B in the treatment of sepsis caused by multi drug resistant Acinetobacter baumannii：
caused by carbapenem-resistant Gram-negative bacteria randomized open label trial[J]. Iran J Pharm Res，2019，18
[J]. Shanghai Med Pharm J，2022，43（13）：26-28，50. （Suppl1）：269-281.
[ 5 ] HIGGINS J P T，ALTMAN D G，GØTZSCHE P C，et al. [16] MIANO T A，LAUTENBACH E，WILSON F P，et al.
The Cochrane collaboration’s tool for assessing risk of Attributable risk and time course of colistin-associated
bias in randomised trials[J]. BMJ，2011，343：d5928. acute kidney injury[J]. Clin J Am Soc Nephrol，2018，13
[ 6 ] STANG A. Critical evaluation of the Newcastle-Ottawa （4）：542-550.
scale for the assessment of the quality of nonrandomized [17] KHALILI H，SHOJAEI L，MOHAMMADI M，et al.
studies in meta-analysis[J]. Eur J Epidemiol，2010，25（9）： Meropenem/colistin versus meropenem/ampicillin-sulbactam
603-605. in the treatment of carbapenem-resistant pneumonia[J]. J
[ 7 ] MOGYORÓDI B，CSÉKÓ A B，HERMANN C，et al. Comp Eff Res，2018，7（9）：901-911.
Ceftolozane/tazobactam versus colistin in the treatment of [18] ZALTS R，NEUBERGER A，HUSSEIN K，et al. Treat‐
ventilator-associated pneumonia due to extensively drug- ment of carbapenem-resistant Acinetobacter baumannii
resistant Pseudomonas aeruginosa[J]. Sci Rep，2022，12 ventilator-associated pneumonia：retrospective comparison
（1）：4455. between intravenous colistin and intravenous ampicillin-
[ 8 ] DOREMUS C，MARCELLA S W，CAI B，et al. Utiliza‐ sulbactam[J]. Am J Ther，2016，23（1）：e78-e85.
tion of colistin versus β-lactam and β-lactamase inhibitor [19] ROCCO M，MONTINI L，ALESSANDRI E，et al. Risk
agents in relation to acute kidney injury in patients with factors for acute kidney injury in critically ill patients
severe Gram-negative infections[J]. Infect Dis Ther，2022， receiving high intravenous doses of colistin methanesulfo‐
11（1）：187-199. nate and/or other nephrotoxic antibiotics：a retrospective
[ 9 ] CHANG K，WANG H B，ZHAO J P，et al. Polymyxin B/ cohort study[J]. Crit Care，2013，17（4）：R174.
tigecycline combination vs. polymyxin B or tigecycline [20] OLIVEIRA M S，PRADO G V，COSTA S F，et al. Ampi‐
alone for the treatment of hospital-acquired pneumonia cillin/sulbactam compared with polymyxins for the treat‐
caused by carbapenem-resistant Enterobacteriaceae or ment of infections caused by carbapenem-resistant Aci‐
carbapenem-resistant Acinetobacter baumannii[J]. Front netobacter spp[J]. J Antimicrob Chemother，2008，61（6）：
Med，2022，9：772372. 1369-1375.
[10] ALMANGOUR T A，ALJABRI A，MUSAWA M A，et al. [21] İPEK M S，AKTAR F，OKUR N，et al. Colistin use in

· 2798 · China Pharmacy 2023 Vol. 34 No. 22 中国药房 2023年第34卷第22期